IgA nephropathy

Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial

The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera

Atacicept Cuts Proteinuria in IgA Nephropathy — How Emerging B‑cell and Complement‑Targeted Therapies Compare